Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heterogeneous nuclear ribonucleoprotein K pseudogene 4 (HNRNPKP4) is classified as a pseudogene—specifically, a noncoding genomic DNA sequence related to the functional gene coding for heterogeneous nuclear ribonucleoprotein K (HNRNPK)[1][3]. Pseudogenes such as HNRNPKP4 typically arise from duplication or retrotransposition events and generally lack protein-coding capability due to disabling mutations. There is no established evidence supporting the direct translation or functional protein product from HNRNPKP4, nor is there evidence that makes it a druggable or therapeutic target[1][3][9]. Its parent gene, HNRNPK, encodes an RNA- and DNA-binding protein with roles in gene regulation, but these functions do not apply to the pseudogene form. The biological relevance of most pseudogenes is limited; in some cases, pseudogenes can affect the expression of their parental genes via transcript-level regulatory mechanisms, but no such activity has been described for HNRNPKP4 specifically[1][5][9]. It is not considered a receptor, enzyme, transporter, or other canonical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein K pseudogene 4 (HNRNPKP4).